Login
$REGN
$807.84 +$2.82 (0.35%) Live

Ownership

13F as of Q2 2026 · 102.8M shares outstanding

Who owns REGN?

By type of holder
Institutions 88.7% Insiders 3.4% Everyone else 7.9%
Concentration Top 10 holders own 42.8%
BlackRock, Inc. 8.9% · Vanguard Capital Management LLC 6.5%
Institutional ownership
88.7%
+0.6 pts vs last qtr
Institutional holders
1,327
-67 vs last qtr
Net shares bought
+644.2K
by institutions in Q2 2026
New / sold out
122 / 189
positions opened vs closed

How is ownership changing?

Institutions, last 8 quarters

Biggest buyers in Q2 2026
  • Vanguard Portfolio Management LLC +1.5M
  • Norges Bank NEW +1.2M

Sign up to see all 5.

Biggest sellers in Q2 2026
  • FMR LLC −686.2K
  • Price T Rowe Associates Inc /MD/ −647.8K

Sign up to see all 5.

Who is planning to sell?

Notices of proposed sale, last 12 months
$12M
13 notices from 8 people
Shares covered
15.3K
0.01% of the company
Arranged in advance
98%
of the value is under a 10b5-1 plan
Under a 10b5-1 plan No plan
$0$1.6M$3.2MNov 2025: $570.0K under a 10b5-1 planNov 2025: $280.6K without a planNovDecJan 2026: $1.2M under a 10b5-1 planJanFeb 2026: $3.2M under a 10b5-1 planFebMarAprMayJunJul 2026: $249.9K under a 10b5-1 planJulAug 2026: $960.0K under a 10b5-1 planAugSep 2026: $2.3M under a 10b5-1 planSepOct 2026: $3.2M under a 10b5-1 planOct
Largest proposed sellers
  • Murphy Andrew J Officer 10b5-1 $3.2M
  • McCourt Marion Officer 10b5-1 $2M

Sign up to see all 5.

Every notice on Red Flags →

A Form 144 is notice of a planned sale, not the sale itself. What insiders actually sold is on Insider Transactions.

Is your stake being diluted?

Diluted share count, FY2016–FY2025
−6.6%
−0.76% a year
Each share's claim on the business
+7.1%
grew without buying or selling a share
Spent on buybacks vs paid in stock
$18.1B vs $6.58B
over 10 fiscal years
Diluted shares, split-adjusted
105.3M111.4M117.5M2016: 116.3M shares'162017: 115.9M shares'172018: 114.8M shares'182019: 114.6M shares'192020: 115.1M shares'202021: 112.2M shares'212022: 113.5M shares'222023: 113.7M shares'232024: 115.1M shares'242025: 108.6M shares'25
Buybacks Stock-based comp
$0$2.92B$5.85B2016 buybacks: $02016 stock comp: $559.9M'162017 buybacks: $02017 stock comp: $507.3M'172018 buybacks: $4.4M2018 stock comp: $427.4M'182019 buybacks: $275.9M2019 stock comp: $464.3M'192020 buybacks: $5.85B2020 stock comp: $432.0M'202021 buybacks: $1.65B2021 stock comp: $601.7M'212022 buybacks: $2.08B2022 stock comp: $725.0M'222023 buybacks: $2.24B2023 stock comp: $885.0M'232024 buybacks: $2.6B2024 stock comp: $982.8M'242025 buybacks: $3.44B2025 stock comp: $993.7M'25

How patient are the owners?

Institutional shares by how long they've been held
5+ years80% 3–5 years8% 1–3 years8% Under 1 year5%
Quarterly turnover
9.4%
of institutional shares changed hands
Top 10 managers, median time held
5 years

Super Investors

Investment managers reporting REGN on Form 13F
B
BlackRock, Inc.
Shares
9.1M
% of company
8.87%
Change vs last qtr
+165.8K (+1.9%)
Held since
≤2021
VC
Vanguard Capital Management LLC
Shares
6.6M
% of company
6.45%
Change vs last qtr
−25.2K (−0.4%)
Held since
≤2021

28 more super investors behind a free account

See every manager holding Regeneron Pharmaceuticals Inc, how their position has changed, and how long they've held it.

Sign up free

Institutional Funds

Mutual funds and ETFs reporting REGN on Form N-PORT; together they hold 40.5% of the company
VT
Position value
$2.04B
% of company
3.18%
% of the fund
0.09%
As of
June 30, 2026
DC
Dodge & Cox Funds
Position value
$1.95B
% of company
3.04%
% of the fund
1.64%
As of
June 30, 2026

23 more funds behind a free account

See every fund holding Regeneron Pharmaceuticals Inc and how much of the fund the position is.

Sign up free

Insiders and 5%+ holders

From Forms 3/4/5 and Schedules 13D/G
YG
Yancopoulos George
Insider
Shares
2.3M
% of company
2.20%
Change vs last qtr
—
Held since
—
SL
Schleifer Leonard S
Insider
Shares
853.8K
% of company
0.83%
Change vs last qtr
—
Held since
—

18 more holders behind a free account

See every insider and 5%+ holder of Regeneron Pharmaceuticals Inc.

Sign up free

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support